The present study evaluated the interaction between the JAK2 and programmed cell death ligand 1 (PD-L1) pathways in triple-negative breast cancer (TNBC). A subset of TNBC tumors had a 9p24.1 amplification encoding JAK2 and PD-L1. We observed a synergy between the JAK2/interferon-g pathway and 9p24.1 amplification, leading to increased PD-L1 expression. Background: Activation of the JAK/STAT pathway is common in triple-negative breast cancer (TNBC) and affects the expression of genes controlling immune signaling. A subset of TNBC cases will have somatic amplification of chromosome 9p24.1, encoding PD-L1, PD-L2, and JAK2, which has been associated with decreased survival. Materials and Methods: Eleven TNBC cell lines were evaluated using array comparative genomic hybridization. A copy number gain was defined as an array comparative genomic hybridization log 2 ratio of ! 1. Cell surface expression of programmed cell death ligand 1 (PD-L1) was detected using flow cytometry and compared with the median fluorescence intensity of isotype control immunoglobulin. To selectively inhibit JAK2, lentiviral vectors encoding 2 different short hairpin RNA (shRNA) were generated. JAK2, STAT1, STAT3, phosphorylated (p) STAT1, and pSTAT3 expression were measured by immunoblot. Statistical significance was defined as P < .05. Results: The cell line HCC70 had 9p24.1 copy number amplification that was associated with both increased JAK2 and pSTAT3; however, knockdown of JAK2 inhibited cell growth independently of 9p24.1 copy number status. In TNBC cell lines with 9p24.1 gain or amplification, PD-L1 expression rapidly and strikingly increased 5-to 38-fold with interferon-g (P < .05), and inducible PD-L1 expression was completely blocked by JAK2 knockdown and the JAK1/2 inhibitor ruxolitinib. In tumor tissue, expression of interferon-gerelated genes correlated with 9p24.1 copy number status. Conclusion: These data suggest that the JAK2/STAT1 pathway in TNBC might regulate the dynamic expression of PD-L1 that is induced in the setting of an inflammatory response. Inhibition of JAK2 might provide a synergistic therapy when combined with other immunotherapies in the subset of TNBC with 9p24.1 amplification.
Introduction
Triple-negative breast cancer (TNBC) contributes to 15% to 20% of newly diagnosed BC cases and has been associated with a poor prognosis. 1 Although the clinical definition of TNBC is determined by the status of the estrogen receptor (ER), progesterone receptor (PR), and ErbB2 (human epidermal growth factor receptor 2 [HER2]), TNBC is a highly heterogeneous disease with ! 4 to 6 subtypes that have been categorized at the genomic level. 2 Increased 1 expression of programmed cell death 1 (PD-1) and its ligands (PDLs) has been reported in multiple human tumors, suggesting that tumors exploit the immune checkpoint pathway to evade immune surveillance. [3] [4] [5] The expression of PD-L1 is associated with an increased somatic mutational burden [6] [7] [8] and neo-epitope formation. 9, 10 Approximately 20% of TNBC tumors express PD-L1, 11 which can be induced in cell lines with paclitaxel chemotherapy. 12, 13 Recent PD-1/PD-L1 blockade clinical trials (pembrolizumab, MPDL3280A) have reported overall response rates of 15% to 20% in PD-L1 þ TNBC. 14, 15 However, clinical studies of targeted checkpoint blockade have been limited by the lack of predictive biomarkers of disease response, the complexity of the tumor genomes and clinical samples, and the degeneracy of the receptoreligand interactions. The PD-L1 and PD-L2 genes localize to chromosome 9p24.1 adjacent to JAK2. JAK2 is a transcriptional activator of both PD-L1 in lymphoma 16 and chromosome 9p copy number gain has been associated with striking therapeutic activity in patients with advanced Hodgkin lymphoma treated with the PD-1 inhibitor nivolumab. 17 However, the effect of 9p24.1 amplification on the PD-L1 pathway in TNBC is much less known. The 9p24.1 amplification has been reported in 4% to 25% of TNBC tumors, and high-level amplification has been associated with worse diseasefree and overall survival. 18, 19 Amplification has been associated with overexpression of JAK2 and PD-L1 mRNA 19 and a functional dependence on JAK2 in a xenogeneic model. 18 Independently of PD-L1, activation of the JAK2/STAT3 pathway, as measured by phosphorylated STAT3 (pSTAT3), is associated with BC metastasis and poor prognosis. 20 Targeted inhibition of JAK2/STAT3 signaling impairs tumor growth and metastasis, suggesting that the JAK2/STAT3 pathway might be an effective therapeutic target in TNBC. 21 Several JAK inhibitors are under clinical investigation in both solid tumors and myeloproliferative disorders. [22] [23] [24] Of these, ruxolitinib (INCB018424) is a JAK1/JAK2 selective inhibitor approved by the Food and Drug Administration for the treatment of myelofibrosis 25 but was recently shown to have limited effect on tumor growth in a xenogeneic model because of concordant JAK1 inhibition. 18 In the present study, we identified cell line models of 9p24.1 amplification in TNBC and determined the association of the copy number on the expression and activation of both the JAK2 and the PD-L1 pathways. We further evaluated the activation status and interactions of the JAK2 and PD-L1 pathways, as a function of copy number gain. We have proposed a model by which the coamplification of JAK2 and PD-L1 enhances the dynamic response of PD-L1 to local inflammatory signals.
Materials and Methods

Cell Lines and Culture
The 13 human BC cell lines were obtained from ATCC (Manassas, VA), which performs cell line characterizations using short tandem repeat profiling and passaged for < 6 months after resuscitation. MCF-7 and MDA-MB-468 were cultured in Dulbecco modified Eagle medium (Gibco, Invitrogen) supplemented with 10% fetal bovine serum and 100 mg/mL penicillin/streptomycin (GE Healthcare, Logan, UT). BT549, SK-BR3, T47D, HCC1937, HCC1428, HCC70, MDA-MB-453, MDA-MB-436, and MDA-MB-231 were cultured in Roswell Park Memorial Institute 1640 medium (Hyclone, Logan, UT) and 100 mg/mL penicillin/streptomycin (GE Healthcare). Interferon-g (IFN-g; Thermo Fisher, Waltham, MA) was stocked at 25 mg/mL in accordance with the manufacturer's instructions for later use. All BC cell lines were maintained at 37 C in 5% carbon dioxide.
Generation of JAK2 Short Hairpin RNA-Transduced Cell Lines
Two short hairpin RNAs (shRNAs) targeting JAK2 and a control scrambled shRNA, were cloned into pLKO.1 lentivirus vector (a generous gift from S. Eaton). The 2 JAK2 shRNA sequences were as follows: 402: 5 0 /3 0 CCGGCCCTGACCCTAAATAATAC ATCTCGAGATGTATTATTTAGGGTCAGGGTTTTT; and 424: 5 0 /3 0 CCGGGCTTTGTCTTTCGTGTCATTACTCGA
GTAATGACACGAAAGACAAAGCTTTTT. HEK293LX cells were cotransfected with the recombinant pLKO.1 plasmids, Gagpol (d8.91), and pCMV-VSVG to produce lentivirus. The targeted BC cell lines were cultured in conditioned medium with Polybrene (Millipore, Billerica, MA) and selected by 600 ng/mL puromycin (Sigma-Aldrich) after 2 days. The efficiency of the JAK2 inhibition was verified by immunoblot.
Short Interfering RNA Knockdown
Short interfering RNA (siRNA) designed to knockdown PD-L1 and a negative control siRNA (nontargeting siRNA) were obtained from Invitrogen (Carlsbad, CA). BC cells were plated in 6-well plates to reach 60% confluency after overnight culture. The PD-L1 siRNA and negative control siRNA were mixed with Lipofactamine-3000 (Invitrogen) and added into the culture medium in accordance with the manufacturer's protocol for 72 hours.
Cell Proliferation Assay
For the JAK2 shRNA, MDA-MB-231, MDA-MB-468, and HCC70 were plated in 96-well plates, each with 4 replicate wells. After 4 days of culture, cellular proliferation was measured using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI), according to the manufacturer's instructions, and detected using a Tecan-5082 Sunrise (Tecan, Männedorf, Switzerland) at 570 nm. For the ruxolitinib assays, MDA-MB-231 and HCC70 were plated into two 96-well plates, each with 12 replicate wells. Ruxolitinib (INCB018424; Selleck Chemicals, Houston, TX) was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich) according to the manufacturer's protocol at 5 mM. The final concentration of ruxolitinib ranged from 0.1 to 25 mM, with 0.5% DMSO used as a control. After 72 hours, cellular proliferation was measured as previously.
Western Blotting Analysis
Cell lysates were prepared with lysis buffer (50 mM Tris at pH 7.4, 10% glycerol, 0.1% sodium dodecyl sulfate, 10 mM sodium fluoride, 2 mM phenylmethylsulfonyl fluoride, and 1 mM dithiothreitol) on ice for 30 minutes. The protein concentrations were quantified using the Bradford assay (Bio-Rad, Richmond, CA). The proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membrane. The membrane was blocked with 5% nonfat milk, followed 
Flow Cytometry
The cells were harvested and washed 3 times with 0.5% bovine serum albumin (BSA)/phosphate-buffered saline (PBS), and 1Â10 6 cells were resuspended in 100 mL of BSA/PBS, incubated with 5 mL of phycoerythrin-conjugated PD-L1 antibody (eBioscience, San Diego, CA) or isotype control (IgG2a-PE, Santa Cruz Biotechnology, Santa Cruz, CA) for 30 minutes on ice, washed with BSA/ PBS buffer 3 times, and resuspended in 400 mL of 0.5% BSA/PBS buffer. Flow cytometry was performed using an Attune acoustic focusing cytometer (Life Technologies).
Array Comparative Genomic Hybridization
DNA was extracted using Qiagen (Hilden, Germany). For each hybridization, 100 ng of genomic DNA from each sample and pooled commercial 46XX (Promega) were amplified using the GenomiPhi amplification kit (GE Healthcare). Subsequently, 1 mg of amplified sample and 1 mg of amplified reference template were digested with DNaseI and labeled with Cy-5 deoxyuridine triphosphate and Cy-3 deoxyuridine triphosphate, respectively, using a BioPrime labeling kit (Invitrogen). All labeling reactions were assessed using a Nanodrop assay before mixing and hybridization to either the 244,000 or 400,000 feature CGH arrays (Agilent Technologies). The array comparative genomic hybridization (aCGH) data were assessed using a series of quality control metrics and analyzed using an aberration detection algorithm. 27 The latter identifies all aberrant intervals in a given sample with consistently high-or low-log ratios according to the statistical score derived from the average normalized log ratios of all probes in the genomic interval multiplied by the square root of the number of these probes. This score represents the deviation of the average of the normalized log 2 ratios from its expected value of 0 and is proportional to the height (absolute average log ratio) of the genomic interval and the square root of the number of probes in the interval.
Nanostring nCounter Analysis
A total of seventeen TNBC tumor samples with predefined positive 9p24.1 status were included in Nanostring analysis. 19 RNA was extracted from fresh-frozen paraffin-embedded sections using the RNeasy FFPE RNA Isolation Kit (Qiagen). RNA quantification was performed using a Qubit, version 2.0, fluorometer (Life Technologies) and Qubit RNA HS assay kit (Molecular Probes, Eugene, OR). The quality of RNA was assessed by spectrophotometric measurement. The Nanostring nCounter PanCancer Immune Profiling Panel (NanoString nCounter), including 770 genes related to the immune response, was used for gene expression detection, in accordance with the manufacturer's instructions. The data were analyzed using Nanostring nSolver Analysis Software, version 2.0. All patients provided written informed consent for the use of their tissue, and the Mayo Clinic institutional review board approved the present study.
Statistical Analysis
One-way analysis of variance was applied to determine any statistically significant differences in the shRNA JAK2 knockdown proliferation assay and flow cytometry. A nonparametric Student t test was used to determine significant differences in baseline PD-L1 expression. Wilcoxon's t test of statistical significance was performed using R language to determine the significance of differences of immune-related gene expression levels, and Benjamini-Hochberg test was used for multiple comparisons. A heat map of RNA expression was generated using gplots and RColorBrewer package of R (R Foundation). Thirty-three validated immune signatures were used, 28 and the gene set enrichment analysis (GSEA) score of each sample was calculated using the R package GSVA. 29 The correlation of RNA expression between the 2 groups was calculated using Spearman's correlation coefficients. Statistical significance was defined as P < .05 or P < adjusted P value if multiple testing correction was applied.
Results
9p24.1 Amplification in TNBC Cell Lines Is Associated With Activated JAK2/STAT3
To identify TNBC cell line models corresponding to the clinically observed 9p24.1 amplification, we performed aCGH on 11 TNBC cell lines ( Figure 1A ). The shortest region of overlap for the amplicon detected in our study included JAK2, PD-L1, and PD-L2. The copy number level of chromosome 9p24.1 was scored (PDJ score) according to the aCGH log 2 ratios. These ranged from À1 (green) to þ2 (red) and included copy number loss (À1), no change (0), gain (0.5-1), and amplification (þ2) of this region (Figure 1 ). Of 11 TNBC cell lines, MDA-MB-436, BT549 and MDA-MB-157 had a copy number gain (aCGH log 2 ratio, þ1, þ1, þ0.5), and the HCC70 cell line had amplification of 9p24.1 (aCGH log 2 ratio, þ2). The array CGH log 2 ratio for 4 cell lines (MDA-MB-468, H4478, HCC1937, and SUM149) was 0, defined as a neutral copy number. MDA-MB-231, MFM-223, and MDA-MB-453 were scored as À1, representing copy number loss (log 2 ratio < 1) at chromosome 9p24.1.
A copy number gain of 9p24.1 was strongly associated with increased JAK2 mRNA expression in tissue samples. 18, 19 We measured JAK2, STAT3, and pSTAT3 protein expression levels in 9 BC cell lines using immunoblot. Compared with the nonamplified cell lines MDA-MB-468 and HCC70 (copy number amplification) had the greatest relative levels of JAK2 (2.2-fold greater). The cell lines with copy number gain (BT549, MDA-MB-436, and HCC70) also expressed a greater level of pSTAT3 comparing with the nonamplified and copy number loss cell lines (P ¼ .03 and P ¼ .01, respectively; Figure 1B ). The basal level of STAT1, STAT3, and pSTAT1 varied among the BC cell lines and was not associated with 9p24.1 amplification status or pSTAT3 level. The ER þ cell line MCF-7 had a high level of JAK2
( Figure 1B ).
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Copy Number Gain of 9p24.1 Is Associated With Functional Activation of JAK2/STAT3
Activation of the JAK2/STAT3 pathway was associated with BC proliferation. 30 To determine the functional effect of JAK2 copy number gain in TNBC, we used 2 shRNAs to target JAK2 expression in MDA-MB-231, MDA-MB-468, and HCC70. All the targeted cell lines significantly decreased the expression of JAK2 by > 90% (Figure 2A ). In addition, the same JAK2 shRNAs inhibited proliferation compared with the control in MDA-MB-231 (P < .0001), MDA-MB-468 (P < .0001), and HCC70 (P < .0001) after 96 hours, regardless of 9p24.1 amplification status ( Figure 2B ). Constitutive activation of STAT3 observed in primary BC contributes to aggressive behavior and a poor prognosis. 31 Activation of pSTAT3 (Tyr705) might be dependent on both JAK1 and JAK2 activity in BC. 18, 23 In Figure 2A , phosphorylation of STAT3 was inhibited by JAK2 shRNA in the MDA-MB-231 and MDA-MB-468 cell lines. For HCC70, the pSTAT3 expression decreased by 75% (shRNA-402) and 25% (shRNA-424) compared with scrambled shJAK2, averaged over 3 independent experiments. We hypothesized that the 9p24. 
Basal Levels of Cell Surface PD-L1 Is Not Altered by JAK2 Inhibition
We performed flow cytometry to measure the expression of PD-L1 in 6 BC cell lines. The median fluorescence intensity (MFI) ratio (MFI of PD-L1/isotype control) was calculated. Basal PD-L1 expression was detected in all 4 TNBC cell lines, with MDA-MB-231 (9p24.1 loss) having the greatest basal level of PD-L1 expression (mean MFI ratio, 17.7) compared with HCC70 (9p24.1 amplification; mean MFI ratio, 11.7; Figure 3A) . In 2 ER þ BC cell lines, MCF-7 and T47D, the basal expression of PD-L1 was not detected by flow cytometry ( Figure 3A) . Therefore, 9p24.1 amplification did not correlate with PD-L1 expression in the TNBC cell lines. This is consistent with a previous study comparing mRNA expression across cell lines in the Broad Institute Cancer Cell Line Encyclopedia database. 32 In lymphoma, it has been reported that PD-L1 expression is dependent on JAK2 expression through STAT1 activation. 22 We hypothesized that JAK2 would regulate PD-L1 baseline expression through the same mechanism in TNBC cell lines. JAK2 expression was inhibited in MDA-MB-231 and HCC70 using 2 different shJAK2 sequences (shJAK2-402, shJAK2-424), and PD-L1 expression was measured by flow cytometry ( Figure 3B ). In MDA-MB-231, shRNA knockdown of JAK2 did not alter PD-L1 cell surface expression (MFI ratio, control ¼ 16.8 vs. sh402 ¼ 15.0 vs. sh424 ¼ 13.8; P ¼ .8; basal level of PD-L1 expression detected in TNBC cell lines is relatively insensitive to JAK2 inhibition and is independent of 9p24.1 amplification status.
9p24.1 Amplification Enhances IFN-geInduced PD-L1 Expression in TNBC
Expression of PD-L1 can be induced by IFN-g in multiple cell types, including TNBC. 32, 33 To determine whether inducible PD-L1 expression in TNBC is associated with 9p24.1 amplification, MDA-MB-231 (9p24.1 loss), MDA-MB-468 (9p24.1 normal), MDA-MB-436 (9p24.1 gain), and HCC70 (9p24.1 amplification) were treated with 10 ng/mL IFN-g or 0.5% DMSO control for 24 hours and PD-L1 expression was measured by flow cytometry. PD-L1 cell surface expression was rapidly induced by IFN-g in TNBC. HCC70 showed the greatest inducible PD-L1 expression (mean MFI ratio, 48.4) compared with MDA-MB-436 (mean MFI ratio, 15.1), MDA-MB-468 (mean MFI ratio, 6.7), and MDA-MB-231 (mean MFI ratio, 19.6), and the inducible level of PD-L1 (MFI-fold increased relative to control) was associated with the 9p24.1 amplification level (P < .05; Figure 4A ). The IFN-g pathway activated STAT1 through JAK1/2. 34 We observed that both STAT1 and pSTAT1 (Tyr701) were significantly increased (>90%) in IFN-getreated MDA-MB-231 and HCC70 ( Figure 4A ). We found that 1 mM of ruxolitinib completely blocks pSTAT1 activation and the overexpression of STAT1 induced by IFN-g. In the JAK2 shRNA-treated cell lines, MDA-MB-231 and HCC70, inhibition of JAK2 markedly blocked the induced, but not the basal level of PD-L1, the upregulation of STAT1, and the phosphorylation of STAT1 ( Figure 4B ). The expression of PD-L1 correlated highly with the level of IFN-g only in tumors with the 9p24.1 copy number gain (r ¼ 0.857; P ¼ .02; Figure 4C ). To evaluate activation of the IFN-g pathway in TNBC tumor tissue, we measured RNA expression of a panel of immune-related genes by Nanostring analysis in 17 TNBC tumors, of which 7 had a copy number gain of 9p24.1. We identified 29 genes with a significant difference (adjusted P < .05) between gain and nongain groups ( Figure 5A ). Of these, 6 genes (PSMB9, PSMB8, TAPBP, HLA-DRB4, HLA-DPA1, VCAM1) were overexpressed in tumors with 9p24.1 copy number gain. All these genes were regulated by IFN-g 35, 36 ( Figure 5C ). PSMB9 and PSMB8 are components of the proteasomal complex. 37, 38 HLA-DRB4 and HLA-DPA1 are major histocompatibility complex class II genes. 39 TAPBP plays a role in major histocompatibility complex class I antigen presentation.
40
VCAM1 functions in cellecell adhesion. 41 To further study the interaction between the 9p24.1 amplicon and the immune environment, we performed GSEA using the 29 selected genes ( Figure 5B ). We observed an IFN-g signature and other tumor infiltrating lymphocytes signatures, including M1 macrophage and T-cell exhaustion signatures. These data suggest that the local immune environment is altered in tumors with a 9p24.1 copy number gain, with the activation of the IFN-g signature and evidence of T-cell exhaustion.
Discussion
Copy number gain at chromosome 9p24.1 is emerging as a potential oncogenic driver for a number of cancers, including TNBC. 19, 22, 42 This region encodes JAK2, PD-L1, and PD-L2; however, the functional effect of co-amplification of these pathways is not well understood. In the present study, we interrogated 11 TNBC cell lines by aCGH for 9p24.1 copy number alterations. Three of these cell lines (eg, HCC70, MDA-MB-436, BT549) had a gain of 9p24.1, comparable with the frequency reported in patient tumors. 19 Ten of these cell lines (all but MFM-223) are included in the Cancer Cell Line Encyclopedia copy number analysis using single nucleotide polymorphism array, 32 and 3 cells lines (MDA-MB-231, MDA-MB-436, and HCC70) have recently been analyzed for 9p24.1 gain using fluorescence in situ hybridization. 18 Our data differ in the relative quantitation of the 9p24.1 copy number from these studies. We detected a high level of copy number (log 2 ratio > 2) in HCC70 and a lower level copy number gain (log 2 ratio < 2) for MDA-MB-436. The discordance might have resulted from the difference in the assays used for copy number quantitation. We also detected 9p24.1 copy number loss in 2 TNBC cell lines, MDA-MB-231 and MFM-223. Activation of the JAK2/STAT3 pathway in TNBC has been associated with inhibition of apoptosis, induction of proliferation, and metastatic potential. 20, 43 Inhibitors targeting the JAK2/STAT3 pathway can effectively block proliferation in TNBC cell lines [44] [45] [46] and in
À stem cell-like BC cells. 20 Our data have demonstrated that JAK2 copy number gain is associated with activation of the JAK2/ STAT3 pathway and cellular proliferation. As expected, the 9p24.1 copy number gain was associated with both increased JAK2 and pSTAT3 protein levels and inhibition of JAK2 by shRNA significantly decreased cell growth, similar to that reported in primary lymphoma and lymphoma cell lines. 16 JAK2 activates other pathways involved in promoting proliferation, 47 and the combination of JAK2-specific inhibitors with the JAK1/2 inhibitor ruxolitinib are synergistic in JAK2-mutant myeloproliferative neoplasm cells. 48 In our study, ruxolitinib failed to inhibit cell growth in MDA-MB-468, MDA-MB-436, and HCC70. We observed that in the setting of 9p24.1 copy number gain in TNBC cell lines, ruxolitinib had a minimal effect on cellular proliferation, despite efficient inhibition of pSTAT3. This might have resulted from the concordant effects on pSTAT6. 18 In our studies, amplification of JAK2 was tightly linked with amplification of both PD-L1 and PD-L2, although the functional significance of PD-L1 amplification on immune regulation and response to checkpoint blockade is not known. Increased expression of PD-L1 has been observed in both TNBC cell lines and 2% to 34% of TNBC tumor tissue. [49] [50] [51] PD-L1 expression is not a reliable predictor of response to checkpoint blockade, 1,52 because PD-L1 À patients might still benefit from treatment. 53, 54 We hypothesized that 9p24.1 amplification would be associated with elevated PD-L1 expression in TNBC cell lines, because amplification is associated with increased expression of PD-L1 RNA in TNBC tissue. 18, 32 However, in all TNBC cell lines tested, we observed that basal PD-L1 expression was elevated but that the absolute level did not correlate with 9p24.1 amplification. In lymphoma cell lines, the basal expression of PD-L1 is regulated through the JAK2/STAT1 pathway. 16, 22 However, in TNBC, we did not observe a significant effect of JAK2 inhibition on the basal expression of PD-L1. One significant difference between lymphoma and TNBC is the potential for autocrine secretion of IFN-g by lymphoma cell lines but not TNBC. 55 IFN-g activation of JAK1/2 and STAT1 induced PD-L1 expression in multiple cell types. 56, 57 We observed that in TNBC cell lines with 9p24.1 copy number gain, PD-L1 expression was markedly and rapidly inducible by low-dose IFN-g in a copynumber dependent manner, mimicking an in situ inflammatory
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response. The induced PD-L1 expression was completely abrogated by JAK2 inhibition through the STAT1 pathway, by both JAK2 shRNA and low-dose ruxolitinib. The activation of IFN-g response elements was also detected in TNBC tumor tissue with 9p24.1 copy number gain. All 6 genes that were significantly overexpressed in TNBC tumor tissue with 9p24.1 copy number gain are known to be inducible by IFN-g, which likely reflects an IFN-geenriched microenvironment. GSEA data revealed both the IFN-g signature and the T-cell exhaustion signature were present in the 9p24.1 gain subset. We predict that 9p24.1 amplification enhances the sensitivity of PD-L1 to the IFN-g/JAK/STAT pathway ( Figure 5D ).
Conclusion
These data suggest that the 9p24.1 amplification might alter the immune microenvironment by increasing the sensitivity of inducible PD-L1 to IFN-g through the activation of the JAK2/STAT1 pathway in TNBC. We observed an association between the IFN-g inducible level of PD-L1 and 9p24.1 copy number status in TNBC in vitro. The dynamic expression of PD-L1 in response to IFN-g might explain, in part, the discordance of PD-L1 expression and the response to PD-1/ PD-L1 checkpoint blockade observed in clinical trials. 15 Thus, the 9p24.1 copy number might be a surrogate biomarker of PD-L1 activity in TNBC. Because inhibition of JAK2 fully blocks the inducibility of IFN-g, inhibition of JAK2 might provide a synergistic effect combined with other immunotherapies in the subset of TNBC with 9p24.1 amplification.
Clinical Practice Points
The 9p24.1 amplification involving JAK2, PD-L1, and PD-L2 has been reported in 4% to 25% of TNBC tumors, with highlevel amplification associated with worse disease-free and overall survival. We observed a cooperative effect of JAK2/PD-L1 amplification via the JAK2/STAT1 signaling axis, and the synergy led to increased PD-L1 expression in vitro. We demonstrated the correlation of amplification and an IFN-g signature in human TNBC tumors. TNBC tumors with 9p24.1 amplification might represent a clinically relevant subtype of BC.
